In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
To read the full story
Related Article
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Silgard 9 Approved for 2-Dose Schedule: MSD
March 9, 2023
- Japan Panel OKs 2-Dose Regimen for Silgard 9 for Girls below Age 15
March 8, 2023
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
- MHLW Panel Members Support Silgard 9 HPV Vaccination for Ages 9-14
August 5, 2022
- MHLW Panel Confirms Positive Cost-Benefit Profile, Efficacy for 9-Valent HPV Vaccine for NIP Inclusion
March 7, 2022
- MSD to Launch Silgard 9 on Feb. 24, but Mass Supply in Japan Unlikely Until 2023
February 5, 2021
- HPV Vaccines Clinically Significant in Japan, PMDA Says in Silgard 9 Review Report
July 28, 2020
- Japan Ob-Gyn Society Lauds Approval of 9-Valent HPV Vaccine, Plaintiffs Renew Protest
July 27, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Reinstate “Active Recommendation” for HPV Vaccines: LDP Lawmakers’ League
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- Japan Approval for MSD’s 9-Valent HPV Vaccine Delayed into July
June 30, 2020
- Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes
June 26, 2020
- Panel OKs Ofev for PF-ILD; Label Expansion for Xtandi/Erleada, Prevenar and More
May 25, 2020
- MSD’s 9-Valent HPV Vaccine Now in Line for June Approval; Eyes on Its Possible Inclusion in National Immunization Program
May 25, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- MSD’s 9-Valent HPV Vaccine Up for Review in 1st Online PAFSC Meeting
April 16, 2020
- MSD’s 9-Valent HPV Vaccine Nearing Finish Line in Japan 5 Years after Filing, but Vaccination Policy Remains Iffy
April 13, 2020
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- MSD Applies for 9-Valent HPV Vaccine
July 29, 2015
BUSINESS
- Majority of PNH Patients Expected to Switch to Novartis’ Fabhalta: Expert
August 30, 2024
- AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
- JCR’s JR-441 Primed for Japan Clinical Trial in MPS IIIA
August 30, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…